PBM Reform: Vertical Integration, Specialty Drug Tracking Among Differences In House v. Senate Bills
Executive Summary
House Energy and Commerce Committee cleared a PBM bill that seems to contain more transparency loopholes and makes more limited policy tweaks to the drug supply chain middleman than the Senate HELP Committee’s bill, but the House-side legislation would pull back the curtain on specialty-drug reimbursement in a way the Senate version does not.
You may also be interested in...
Are Fees The New Rebates? PhRMA Highlights Shifts In PBM Practices As House Tees Up Reform Vote
Pharmacy benefit managers are increasingly making money off new types of fees tied to list prices, drug industry lobby says, highlighting importance of delinking all PBM compensation from the cost of medicines. Most Congressional proposals in play do not include delinkage provision.
Down But Not Out: The Pharma Policies That Still May Ride With Senate Finance’s PBM Reform
A new biosimilar payment boost, a true, but more limited patient-directed pass-through rebate plan, and product hopping legislation are among the more than two-dozen amendments that could be added to the Senate Finance Committee’s PBM reform package.
Biosimilars Could Give Brands the Boot Mid-Year Under Amendment Added to Senate PBM Reform Bill
However, the low CBO score attached to the measure may suggest PBMs might not be incentivized to follow through on the congressional permission.